Buy these 2 ASX health-tech shares that are ready to rocket: Wilson

The health sector is seen by many experts as one that could remain resilient through times of economic distress.

After all, people may cut out dining out or buying a new sofa, but they will still want to remain physically and mentally well.

And with interest rate rises now biting Australian consumers hard, that scenario is well and truly in play.

Here are two ASX shares involved in healthcare that Wilson Asset Management analysts are rating as buys at the moment:

'Momentum is really strong'

The Aroa Biosurgery Ltd (ASX: ARX) has amazingly rocketed almost 46% over the past 12 months, over a time when few non-mining stocks can even claim to be in the black.

Wilson equity dealer William Thompson reckons that trend will continue, calling it a buy.

"It posted a really good sales update in January," Thompson said in a Wilson video.

"They're a New Zealand-based company… They have about seven different products which they're selling in the US."

Aroa Biosurgey is involved in a joint venture with US partner TELA Bio Inc (NASDAQ: TELA), whose reporting next week could prove to be yet another catalyst for the ASX stock.

With a March year end, Aroa's annual result is not far away.

"The momentum is really strong for the company, so it's a buy."

Thompson's peers unanimously agree, with all five analysts surveyed on CMC Markets currently rating Aroa Biosurgery as a buy.

This stock could go anywhere now that supply problems are waning

Resmed CDI (ASX: RMD) has been an old favourite for health investors for decades now, but the share price has struggled in recent times.

Over the past 18 months the stock has lost more than 21% of its value.

According to Wilson equity analyst Anna Milne, the troubles for the business are temporary.

"They've been really struggling to get [computer] chips," she said.

"Now as the broader demand for electronics wanes in this more challenging environment, [Resmed] will find it a lot easier to get these semiconductor chips."

So once that supply problem is fixed, the sky's the limit for the sleep apnoea device market leader.

That's because its nearest rival, Koninklijke Philips NV (AMS: PHIA), was forced out due to a safety recall just under two years ago. 

"With their major competitor Philips still largely out of the market, and will at least be distracted for a few years, we think Resmed is a great company at a fair valuation."